Doctor, will radiotheranostics make me radioactive?
You’ve been asking for it, and we did it! The [...]
The Michael Hofman Masterclass
Event: The Michael Hofman Masterclass: PSMA - A new era [...]
EANM response to ASTRO’s framework for trainees
Letter to Editor for “European Association of Nuclear Medicine (EANM) [...]
Cost-Effectiveness Analysis of Lu-177-PSMA-617
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant [...]
A major component to successfully establish radioligand therapy
Tackling the Last Mile: A major component to successfully establish [...]
Happy New Year !
From all of us at the Oncidium foundation to you [...]
European Commission approves Pluvicto™
European Commission Approves Pluvicto for PSMA-Positive mCRPC OncLive, Dec 14, [...]
Novel PET Agent to Identify Patients for Targeted Therapies
Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for [...]
Quo Vadis, Teragnosis?
Vercher-Conejero JL. Quo Vadis, Teragnosis? Rev Esp Med Nucl Imagen [...]
The Cary M. Adams Fund
Improving access to radiotheranostics for cancer patients in the US [...]